Monitoring Oedema in Heart Failure to Improve Function and Reduce Hospitalisation Risk
This study will evaluate the Heartfelt device, a novel, passive monitoring system that detects early signs of fluid build-up in patients (oedema) with heart failure by measuring changes in foot and lower leg volume through capture of 3D images. The trial will assess whether this device, when added to standard NHS care, improves quality of life and reduces heart failure-related events compared to standard care alone.
• Adults \>18 years
• Diagnosis of heart failure (any aetiology or left ventricular ejection fraction classification), any timeframe
• Currently prescribed ≥40 mg/day of furosemide (or equivalent loop diuretic) for at least one month.
• Heart failure hospital admission and moderate or severe leg oedema in the previous 12 months.
• Lives in the UK, with a home environment suitable for installation of the Heartfelt device.